1-(((ethylthio)carbonyl)oxy)-2-methylpropyl pivalate

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代缩醛
• 英文名称: 1-(((ethylthio)carbonyl)oxy)-2-methylpropyl pivalate
• 英文别名: (1-Ethylsulfanylcarbonyloxy-2-methylpropyl) 2,2-dimethylpropanoate；(1-ethylsulfanylcarbonyloxy-2-methylpropyl) 2,2-dimethylpropanoate
• 化学式: C₁₂H₂₂O₄S
• 分子量: 262.37
• InChiKey: XJXWZBNOAIXACO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  77.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(((ethylthio)carbonyl)oxy)-2-methylpropyl pivalate 在 过氧乙酸 作用下， 以 二氯甲烷 、 溶剂黄146 为溶剂， 反应 5.42h， 生成 isopropyl 6-diazo-2-(((2-methyl-1-(pivaloyloxy)propoxy)carbonyl)amino)-5-oxohexanoate
  参考文献：
  名称：

  [EN] PRODRUGS OF GLUTAMINE ANALOGS
  [FR] PROMÉDICAMENTS D'ANALOGUES DE GLUTAMINE

  摘要：

  公开号：

  WO2017023774A9
• 作为产物：
  描述：

  1-氯-2-甲基氯甲酸甲酯 在 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 乙醚 为溶剂， 反应 93.0h， 生成 1-(((ethylthio)carbonyl)oxy)-2-methylpropyl pivalate
  参考文献：
  名称：

  [EN] PRODRUGS OF GLUTAMINE ANALOGS
  [FR] PROMÉDICAMENTS D'ANALOGUES DE GLUTAMINE

  摘要：

  公开号：

  WO2017023774A9

文献信息

• Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
  申请人：Gallop A. Mark

  公开号：US20050107334A1

  公开（公告）日：2005-05-19

  The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.

  本文涉及的内容通常与(±)-4-氨基-3-(4-氯苯基)丁酸及其类似物的酰氧基烷基氨基甲酸酯前药、其制药组合物、制备(±)-4-氨基-3-(4-氯苯基)丁酸及其类似物的前药的方法、使用(±)-4-氨基-3-(4-氯苯基)丁酸及其类似物的前药的方法，以及治疗或预防常见疾病和/或疾病，如痉挛和/或酸反流病的制药组合物。本文还涉及适用于口服和口服缓释剂型的(±)-4-氨基-3-(4-氯苯基)丁酸及其类似物的酰氧基烷基氨基甲酸酯前药。
• ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS
  申请人：Gallop Mark A.

  公开号：US20090234138A1

  公开（公告）日：2009-09-17

  The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.

  本文披露了关于(±)-4-氨基-3-(4-氯苯基)丁酸及其类似物的酰氧基烷基氨基甲酸酯前药、其制药组合物、制备(±)-4-氨基-3-(4-氯苯基)丁酸及其类似物的前药的方法、使用(±)-4-氨基-3-(4-氯苯基)丁酸及其类似物的前药的方法，以及用于治疗或预防普通疾病和/或紊乱，如痉挛和/或酸反流病的制药组合物。本文还涉及适用于口服的(±)-4-氨基-3-(4-氯苯基)丁酸及其类似物的酰氧基烷基氨基甲酸酯前药以及其持续释放口服剂型。
• ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE
  申请人：Gallop A. Mark

  公开号：US20080096960A1

  公开（公告）日：2008-04-24

  The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.

  本文涉及到(±)-4-氨基-3-(4-氯苯基)丁酸和其类似物的酰氧基烷基氨基甲酸酯前药、其制药组合物、制备(±)-4-氨基-3-(4-氯苯基)丁酸和其类似物的前药的方法、使用(±)-4-氨基-3-(4-氯苯基)丁酸和其类似物的前药的方法，以及其制药组合物用于治疗或预防常见疾病和/或疾病，如痉挛和/或酸逆流病。本文还涉及适用于口服的酰氧基烷基氨基甲酸酯前药和其持续释放口服剂型。
• Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
  申请人：XenoPort, Inc.

  公开号：EP2354120A1

  公开（公告）日：2011-08-10

  The present invention relates to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-fluorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-fluorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-tluorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The present invention also relates to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-fluorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.

  本发明涉及(±)-4-氨基-3-(4-氟苯基)丁酸及其类似物的酰氧基烷基氨基甲酸酯原药、其药物组合物、(±)-4-氨基-3-(4-氟苯基)丁酸及其类似物的原药制造方法、(±)-4-氨基-3-(4-氟苯基)丁酸及其类似物的原药的使用方法、其药物组合物，用于治疗或预防常见疾病和/或紊乱，如痉挛和/或反酸疾病。本发明还涉及适合口服的(±)-4-氨基-3-(4-氟苯基)丁酸的酰氧基烷基氨基甲酸酯原药及其类似物，以及其缓释口服剂型。
• Prodrugs of glutamine analogs
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US10336778B2

  公开（公告）日：2019-07-02

  The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2′, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.

  本公开提供了具有式 (I) 的化合物： 及其药学上可接受的盐，其中R1、R2、R2′和X如说明书中所定义。具有式（I）的化合物是释放谷氨酰胺类似物的原药，例如 6-重氮-5-氧代-L-正亮氨酸（DON）。本公开还提供了用于治疗癌症的具有式（I）的化合物。